All News

2021

January

Media Release / Jan 14, 2021

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

Read More
Media Release / Jan 11, 2021

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Read More
2020

December

Media Release / Dec 18, 2020

Novartis receives complete response letter from U.S. FDA for inclisiran

Read More
Media Release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Read More
Media Release / Dec 16, 2020

Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G

Read More
Media Release / Dec 16, 2020

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF

Read More
Media Release / Dec 15, 2020

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema

Read More
Media Release / Dec 14, 2020

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Read More
Media Release / Dec 11, 2020

Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More